HCVNS3 Variants in HIV/HCV Coinfected Patients Before-After PegIFN/Ribavirin
Background: Background: This study was designed to characterize HCV NS3 protease resistance associated variants (RAVs) by deep sequence analysis at baseline and after 12 weeks of PegIFN /ribavirin treatment in subjects who failed to achieve an early viral response. Overall genetic variability at NS3 protease drug resistant sites was also assessed. Methods: Subjects and Methods:…